Keypoint: The concurrent administration of bivalent mRNA COVID-19 boosters and influenza vaccines should be considered as a strategy to potentiate neutralizing antibody responses against SARS-CoV-2.
No significant between-group differences were observed in IgM, IgG2, IgG3, IgG4, and IgA responses, nor in nAb responses to SARS-CoV-2 nucleocapsid.
In an exploratory analysis, patients in the concurrent administration group exhibited increased IgG1 responses to all Spike variants relative to those in the separate administration group. They also exhibited increased pseudovirus neutralization to both BA.5 and XBB.1.5 at the time of peak immunogenicity and at 6 months.
At approximately 6 months following vaccine administration, the researchers observed no between-group differences in influenza hemagglutinin responses on the basis of vaccination schedule.
Study limitations include the small and unbalanced patient population, the narrow definition of peak immunogenicity, and the inability to capture data on the ways in which adenovirus and protein-based COVID-19 vaccine boosters affect influenza responses generated by inactivated and live-attenuated vaccines.
“Our results suggest that concurrent administration of these vaccines should be considered as a strategy to potentiate antibody responses to the COVID-19 vaccine and possibly improve vaccine effectiveness,” the researchers concluded.
Disclosures: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Note: This article originally appeared on Infectious Disease Advisor
Comments